Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AbbVie Acquires Aliada for $1.4B | Contract Pharma

What are you searching for?

Sign in
Breaking News

AbbVie Acquires Aliada for $1.4B

Acquisition adds ALIA-1758, a potential best-in-class disease-modifying therapy for Alzheimer's disease.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

AbbVie has completed its previously announced acquisition of Aliada Therapeutics, a biotechnology company developing therapies using a novel blood-brain barrier (BBB)-crossing technology for central nervous system (CNS) diseases. The transaction was valued at $1.4 billion.
 
Aliada’s lead investigational asset utilizing its delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer’s disease.
 
“Alzheimer’s disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age,” said Dawn Carlson, M.D., M.P.H., vice president, neuroscience development at AbbVie. “With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer’s disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada’s novel CNS drug delivery platform.”
 
“We are pleased to announce the acquisition of Aliada by AbbVie and are excited about AbbVie’s commitment to bringing ALIA-1758 to patients with Alzheimer’s disease. Our proprietary MODEL platform has enabled the development of ALIA-1758, a promising step forward in brain delivery of an anti-amyloid antibody therapy,” said Michael Ryan, M.D., chief medical officer at Aliada Therapeutics.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters